MIV THERAPEUTICS SUCCESSFULLY COMPLETES ANIMAL FEASIBILITY STUDIES OF STROKE-PREVENTION DEVICES

MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has successfully completed Phase I animal feasibility studies in sheep of two models of a novel implantable arterial filtration technology device designed to prevent strokes by diverting embolic particles flowing through the bloodstream. These two models of MIVT's unique Aortic Embolic Protection Device (AEPD) are being designed to prevent both major types of embolic strokes -- those triggered by heart surgery and catheterization, and those that occur naturally, not in connection with such procedures.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1011579XSL_NEWSML_TO_NEWSML_WEB.xml)